Recent cancer research at Immunomedics (IMMU) is very interesting. Know of other cancer research?

IMMU has studied how cancer migrates from the colon to the liver. Another company, Cytogen (CYTO), has some interesting research, yet both IMMU and CYTO aren't in the headlines. Maybe their line of investigation is unortohdox.

Recent cancer research at Immunomedics (IMMU) is very interesting. Know of other cancer research?
Australian-developed vaccine prevents cervical cancer





A major international trial has confirmed the effectiveness of a cervical cancer vaccine developed in Australia.





The vaccine was created by Professor Ian Frazer, who is from Brisbane's Centre for Immunology and Cancer Research.





Trials on 12,000 women from 13 countries, which have been sponsored by US drug company Merck, show the treatment is 100 per cent effective in preventing the most common form of cervical cancer.





The vaccine works by blocking two strains of the sexually transmitted human papilloma virus (HPV), which causes up to 70 per cent of cervical cancers.





Dr Eliav Barr, from Merck research laboratories, says more than 50 per cent of women will become infected with HPV at some point during their lives.





"Not all HPV infections are dangerous, most go away by itself," he said.





"But some HPV types, specifically the cancer-causing HPV types, can lead to cervical cancer."





The vaccine is one of two being trialed to prevent the disease, which causes more than 280,000 deaths each year worldwide.





"This trial confirms that a vaccine can give young women a high level of protection from developing precancerous lesions and early cervical cancers," said Laura Koutsky, a professor of epidemiology at the University of Washington, who led the study.





Merck, which licensed the vaccine technology from Australian blood products and vaccine developer CSL Ltd, plans to seek US approval for the cancer vaccine, which is called Gardasil.





Merck, whose earnings plunged after the withdrawal last year of its Vioxx arthritis drug, is partnering its vaccine in Europe with Sanofi-Aventis.





Half the women in the Phase III trial received three doses of Gardasil over a six-month period, while the other women received placebos.





The women were then followed for an average of 17 months.





Gardasil is slated to compete with GlaxoSmithKline Plc's experimental Cervarix cervical cancer vaccine, which targets the same two cancer-causing virus types, but is expected to be approved later than the Merck product.
Reply:Glycogenesis, Inc. have been making some interesting strides in cancer research.





Take a look:


http://www.glycogenesys.com/what.html
Reply:54 forms of cancer have been reversd with glyconutrients.





Read information on my page and Sugars That Heal